Therefore, these novel sorafenib analogues, SC-1 and SC-43, induced apoptosis through SHP-1-dependent STAT3 inactivation and demonstrated more potent apoptotic effects than sorafenib in human breast cancer cells. The gene discussed is NR0B2; the disease is breast carcinoma.